Skip to content
Dosage GuideResearch Reference

Orexin-A Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Orexin-A. All information is for educational purposes only.

Quick Answer

Orexin-A is primarily used in research settings to study sleep-wake regulation, appetite, and reward pathways. Direct administration in humans is limited. Preclinical studies typically use intracerebroventricular (ICV) injections or intravenous administration. No established human dosage exists. Future orexin receptor agonists may have clinical dosing guidelines.

→ Orexin-A Benefits→ Orexin-A Side Effects→ Full Orexin-A Profile
Table of Contents

Standard Dosage Range

Research dosing range: Not applicable (research use only)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Sleep-Wake Regulation Research

1-10 pmol (ICV)Single administration
Duration

Acute effect

Used in animal models to investigate wake-promoting effects. ICV administration allows direct access to the brain.

Appetite and Metabolism Studies

1-10 nmol (IV)Single administration
Duration

Acute effect

Used in animal models to study orexin's role in appetite regulation and energy expenditure. IV administration allows systemic effects.

Reward Pathway Investigations

0.1-1 nmol (into VTA)Single administration
Duration

Acute effect

Used in animal models to examine orexin's influence on dopamine release and reward-seeking behavior. Targeted microinjection into the ventral tegmental area (VTA).

Timing & Frequency

In research settings, Orexin-A is typically administered during the light/inactive phase to observe wake-promoting effects. The timing depends on the specific research question and experimental design.

Cycle Guidance

Orexin-A is generally not used in cyclical patterns due to its acute effects and research-oriented applications. The focus is on single or short-term administrations to study specific physiological responses.

Reconstitution Reference

Quick reference for reconstituting Orexin-A. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg per vial (research grade)
BAC Water Volume1 mL sterile saline for 1 mg/mL concentration
Concentration & DrawAt 1 mg/mL: varies depending on experimental dose required (e.g., 1 pmol = 1.28 ng)
StorageStore lyophilized powder at -20°C. Reconstituted solution should be used immediately or aliquoted and stored at -80°C.
StabilityLyophilized powder stable for several years at -20°C. Reconstituted solution degrades quickly, use within hours or flash freeze for longer storage.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dosage of Orexin-A used in research?
Dosages in animal studies range from picomoles (ICV) to nanomoles (IV or direct microinjection) depending on the route of administration and the target system (brain, periphery). Human dosage is not established.
How is Orexin-A administered in research studies?
Common routes of administration include intracerebroventricular (ICV) injection, intravenous (IV) injection, and direct microinjection into specific brain regions like the VTA. Oral bioavailability is expected to be poor, making injections necessary for research.
What is the stability of reconstituted Orexin-A?
Reconstituted Orexin-A is relatively unstable. It is recommended to use it immediately or aliquot and flash freeze for long-term storage at -80°C to minimize degradation.

Last updated: 2026-02-19